New drug hope for stem cell transplant complication

NCT ID NCT05531786

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 5 times

Summary

This study tests a drug called pacritinib in people with moderate or severe chronic graft-versus-host disease (cGVHD) after a stem cell transplant. cGVHD is an immune disorder that can damage organs and cause disability. Participants must be 18 or older and have not responded to at least two prior treatments. They will take pacritinib capsules daily for 6 to 12 months, with regular checkups to monitor safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pacritinib
What this could lead to: If it works, this could offer a new treatment option for people with chronic graft-versus-host disease that hasn't responded to other therapies.
What could go wrong: This is an early-phase trial with only 50 participants, so results may not apply to everyone. The drug may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic graft versus host disease Fibrosis graft versus host disease Inflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRAFT VS HOST DISEASE

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States
University of Miami
RECRUITING

Miami, Florida, 33101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.